Drug intelligence / Profile preview

AST-12X

Development stage: Preclinical
Modality: Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics

Overview

AST-12X is a therapeutic vaccine currently in the discovery phase of development, primarily targeting neoplasms (cancers). As a therapeutic vaccine, it is designed to stimulate the immune system to recognize and attack cancer cells. Detailed information about its specific mechanism of action, molecular targets, or clinical data beyond its classification as a therapeutic vaccine for neoplasms has not been disclosed publicly[1].

Beyond the preview

Go deeper on AST-12X.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AST-12X.

Explore the full profile